Article

Baxter Seeks Approval for Hemophilia A Drug

Baxter International has submitted a biologics license application to the FDA for its investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on antihemophilic factor.

Baxter International has submitted a biologics license application to the FDA for its investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on antihemophilic factor (recombinant) (ADVATE).

A study of the drug known as BAX 855 among more than 130 previously treated patients showed promise in preventing bleeding episodes, according to a press release from Baxter.

A twice-weekly prophylactic regimen resulted in a 95% reduction in median annualized bleed rate compared with on-demand treatment, according to Baxter. Beyond prevention, BAX 855 showed an aptitude in treating bleeding episodes; 96% of these episodes were controlled with 1 or 2 infusions.

Three patients reported experiencing headaches, but no other adverse side effects were reported.

“The evidence from our late-stage controlled trial showcases that BAX 855 could become an important new treatment option for people with hemophilia A, expanding on more than a decade of experience with ADVATE,” said John Orloff, MD, vice president and global head of research and development for Baxter BioScience, in a press release. “BAX 855 represents our continued commitment to developing valuable new options for the hemophilia community that address the needs of patients around the world.”

A phase 3 study of previously treated patients under the age of 12 with severe hemophilia A is ongoing, according to Baxter.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com